Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Cross Above 200 Day Moving Average - Time to Sell?

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.54 and traded as high as $5.12. Vanda Pharmaceuticals shares last traded at $5.02, with a volume of 703,151 shares traded.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on VNDA. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th. Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. Finally, Wall Street Zen upgraded shares of Vanda Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, June 14th.

Vanda Pharmaceuticals Stock Performance

The firm's 50-day moving average is $4.49 and its two-hundred day moving average is $4.54. The stock has a market cap of $279.33 million, a P/E ratio of -6.32 and a beta of 0.68.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. The company had revenue of $50.04 million during the quarter, compared to analysts' expectations of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 21.98% and a negative return on equity of 8.30%. As a group, research analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 7,000 shares of the company's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $4.59, for a total transaction of $32,130.00. Following the completion of the sale, the director owned 97,082 shares in the company, valued at approximately $445,606.38. The trade was a 6.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Wednesday, May 21st. The shares were purchased at an average cost of $4.40 per share, for a total transaction of $44,000.00. Following the purchase, the chief executive officer directly owned 2,325,731 shares in the company, valued at $10,233,216.40. The trade was a 0.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 10.00% of the company's stock.

Institutional Trading of Vanda Pharmaceuticals

Large investors have recently made changes to their positions in the company. Quantinno Capital Management LP bought a new stake in shares of Vanda Pharmaceuticals in the 4th quarter valued at $48,000. PVG Asset Management Corp bought a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at $48,000. Linden Thomas Advisory Services LLC bought a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at $49,000. Nations Financial Group Inc. IA ADV bought a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at $67,000. Finally, XTX Topco Ltd bought a new stake in shares of Vanda Pharmaceuticals in the 4th quarter valued at $69,000. Institutional investors own 88.14% of the company's stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.